An update from Intron Technology Holdings Ltd. ( ($HK:1760) ) is now available. Intron Technology Holdings Ltd. has entered into a facility ...

It may be time to rethink certain genetic mutations associated with two devastating neurodegenerative disorders—amyotrophic ...

iNtRON has been conducting researches mainly focused on lytic bacteriophages for securing IR candidates and obtaining Open Reading Frames (ORFs) within its genomes.

iNtRON has been actively discussing the exclusive license agreement with Basilea, who showed keen interest in SAL200. It was determined that Basilea is a suitable partner for the further ...

BOSTON and SEOUL, South Korea, July 11, 2022 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com) announced today that CDL200, a novel biological drug candidate under the ...

Intron’s key semiconductor supplier, Infineon, could also change distributors and it would take Intron time to learn about the semiconductors from a new supplier and redo its key designs.

Gram-negative bacterial infections are becoming an increasingly serious global health issueU.S. patent applications filed for three novel drug candidates: PKL200, TSL2200, and EAL2200Continued ...

Dr. KANG, Sang Hyeon, CTO of iNtRON said, "We believe that the recently secured efficacy results are very important and required data to seek a licensing partner for the collaboration of the ...

iNtRON Bio has been developing PHAGERIA Ⓡ, an immunotherapeutic targeting gut bacteria, and through the IMPA™ phage engineering technology developed in-house, iNtRON Bio has secured a new drug ...

iNtRON's PHAGERUS ® platform technology is being developed on the hypothesis that bacteriophage plays an instrumental role to maintain immune system in human beyond the common concept of ...